- Title
- Inhibiting human dipeptidyl peptidase IV using cannabinoids and Leonotis leonurus extracts as a potential therapy for the management of diabetes
- Creator
- Mkabayi, Lithalethu
- Creator
- Viljoen, Zenobia
- Creator
- Lobb, Kevin A
- Creator
- Pletschke, Brett I
- Creator
- Frost, Carminita L
- Subject
- To be catalogued
- Date Issued
- 2023
- Date
- 2023
- Type
- text
- Type
- article
- Identifier
- http://hdl.handle.net/10962/452745
- Identifier
- vital:75167
- Identifier
- xlink:href="https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0043-1773924"
- Description
- Diabetes is a chronic metabolic disorder that has been shown to affect a growing number of people worldwide. Controlling blood glucose levels is one of the possible strategies to treat type 2 diabetes mellitus (T2DM). It has been established that the inhibition of dipeptidyl peptidase IV (DPP-IV) prolongs the activity of incretin hormones, which serve as key stimulators of insulin secretion and regulation of blood glucose levels. Although several synthetic DPP-IV inhibitors are available, there is still a need for naturally sourced inhibitors that have fewer to no undesirable side effects. In this study, cannabinoids and Leonotis leonurus aqueous extracts were evaluated for their inhibitory effects against recombinant human DPP-IV. Their potential inhibition mechanism was explored using in vitro and in silico approaches. All tested cannabinoids and L. leonurus aqueous extracts showed significant inhibitory activity against DPP-IV. Phytochemical analysis of L. leonurus extract indicated the presence of diterpenoids and alkaloids, which might contribute to the inhibitory activity. In molecular docking studies, among different constituents known in L. leonurus, luteolin and marrubiin showed binding energy of -7.2 kcal/mol and cannabinoids (cannabidiol, cannabigerol, cannabinol and Δ9-tetrahydrocannabinol) showed binding energies ranging from -6.5 to -8.2 kcal/mol. Molecular dynamics revealed that all tested compounds formed stable complexes with the enzyme during 100 ns simulation, indicating that they are good ligands. This study provided preliminary evidence for the potential application of the selected cannabinoids and L. leonurus in maintaining glucose homeostasis, suggesting that they could be suitable therapeutic candidates for managing T2DM.
- Format
- computer
- Format
- online resource
- Format
- application/pdf
- Format
- 1 online resource (11 pages)
- Format
- Publisher
- Thieme Gruppe
- Language
- English
- Relation
- Planta Medica
- Relation
- Mkabayi, L., Viljoen, Z., Lobb, K., Pletschke, B. and Frost, C., 2023. Inhibiting human dipeptidyl peptidase IV using cannabinoids and Leonotis leonurus extracts as a potential therapy for the management of diabetes. Planta Medica, 89(14), pp.P-037
- Relation
- Planta Medica volume 89 number 14 p. 037 2023 1439-0221
- Rights
- Publisher
- Rights
- Use of this resource is governed by the terms and conditions of the Thieme Privacy Statement (https://www.thieme.de/de/thieme-gruppe/privacy-policy-statement-Thieme-EN.htm)
- Rights
- Closed Access
- Hits: 103
- Visitors: 97
- Downloads: 2
Collections
Krause, Rui Werner Maçedo (Prof)
Lobb, Kevin Allan (Assoc Prof)
Pletschke, Brett (Prof)
RU Department of Chemistry
RU Department of Biochemistry, Microbiology and Bioinformatics
SDG 03. Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | SOURCE1 | Inhibiting human dipeptidyl peptidase IV using cannabinoids and Leonotis leonurus extracts as a potential therapy for the management of diabetes.pdf | 690 KB | Adobe Acrobat PDF | View Details Download |